Vortosiran
Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3061406-99-0
- Formule: C463H620F7N154O291P39S6
- Masse moléculaire:14532.10
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
|
FXI |
ASGPR |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female C57BL/6J mice[2]
-
Dosage:1, 3 and 9 mg/kg
-
Administration:s.v.; single dose
-
Result:Prevented arterial and venous thrombosis, but tail bleeding did not prolong.
Chemical Information
-
CAS No. 3061406-99-0
-
Appearance Solid
-
Masse moléculaire 14532.10
-
Formule C463H620F7N154O291P39S6
-
Color White to off-white
-
SMILES
[Vortosiran]
-
Synonyms
RBD4059
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Références
[1]. Gabrielsen A, et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood advances. 2026 Apr 14;10(7):2541-2548. [Content Brief]
[3]. Yuan H, et al. Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. Front Immunol. 2026 Oct 5;17:1925585. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Vortosiran
- 3061406-99-0
- RBD4059
- RBD 4059
- RBD-4059
- Small Interfering RNA (siRNA)
- Factor XI
- Asialoglycoprotein Receptor (ASGPR)
- Asialoglycoprotein Receptor
- Ashwell-Morell Receptor
- coagulation factor XI
- small interfering RNA
- N-acetylgalactosamine
- prothrombin time
- antithrombotic effects
- intravascular thrombosis
- hemostasis
- Inhibitor
- inhibitor
- inhibit